Epicardial and endocardial electrophysiological guided thoracoscopic surgery for atrial fibrillation: A multidisciplinary approach of atrial fibrillation ablation in challenging patients  by Krul, Sébastien P.J. et al.
International Journal of Cardiology 173 (2014) 229–235
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdEpicardial and endocardial electrophysiological guided thoracoscopic
surgery for atrial ﬁbrillation: A multidisciplinary approach of atrial
ﬁbrillation ablation in challenging patients☆Sébastien P.J. Krul a,1, Laurent Pison b,1, Mark La Meir c, Antoine H.G. Driessen a, Arthur A.M. Wilde a,
Jos G. Maessen c, Bas A.J.M. De Mol a, Harry J.G.M. Crijns b, Joris R. de Groot a,⁎
a Heart Center, Department of Cardiology, Cardiothoracic Surgery and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands
b Department of Cardiology, Academic Hospital Maastricht and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
c Department of Cardiac Surgery, Academic Hospital Maastricht and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands☆ All authors take responsibility for all aspects of the reli
the data presented and their discussed interpretation.
⁎ Corresponding author at: Department of Cardiolo
Meibergdreef 9, 1100 DD Amsterdam, The Netherla
fax: +31 20 5669618.
E-mail address: j.r.degroot@amc.uva.nl (J.R. de Groot)
1 Both authors contributed equally to this manuscript.
http://dx.doi.org/10.1016/j.ijcard.2014.02.043
0167-5273/© 2014 Elsevier Ireland Ltd. All rights reserveda b s t r a c ta r t i c l e i n f oArticle history:
Received 30 September 2013
Received in revised form 20 January 2014
Accepted 22 February 2014
Available online 28 February 2014
Keywords:
Atrial ﬁbrillation
Thoracoscopic surgery
Electrophysiological mapping
Introduction: Patients with atrial ﬁbrillation (AF) with enlarged atria or previous pulmonary vein isolation (PVI)
are challenging patients for catheter ablation. Thoracoscopic surgery is an effective treatment for these patients
but comes at the cost of an increase in adverse events. Recently, electrophysiological (EP) guided approaches to
thoracoscopic surgery have been described which consist of EP guidance by measurement of conduction block
across ablation lines. In this study we describe the efﬁcacy and safety of EP-guided thoracoscopic surgery for
AF in patients with enlarged atria and/or prior failed catheter ablation.
Methods & results:A total of 72 patientswere included. Two different approaches to EP-guided thoracoscopic sur-
gery were implemented: epicardial or endocardial EP-guidance at the time of surgery. Residual intraoperative
conduction requiring additional ablation was detected with epicardial or endocardial mapping techniques in
50% and 11%, respectively. Additional epicardial or endocardial ablation was performed until bidirectional
blockwas conﬁrmed. Follow-up consisted of an ECG and a 24 h Holter at 3, 6 and 12 months after the procedure.
A total of 57 patients (79%) had freedom of AF andwere off anti-arrhythmic drugs at one year follow-up (30 par-
oxysmal (83%), 27 persistent AF (75%)). Adverse events occurred in 13 patients (6 major). None of our patients
died and all events were reversible.
Conclusion: EP-guidance of thoracoscopic surgery can be safely performed both epicardially and endocardially
and is associated with a high rate of long-term maintenance of sinus rhythm in patients with enlarged atria
and/or a previously failed ablation.© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Atrial ﬁbrillation (AF) is a growing problem in Western society and
associated with a substantial healthcare expenditure [1]. Treatment of
AF is difﬁcult in patients who remain symptomatic despite anti-
arrhythmic therapy, among others hampered by side effects of anti-
arrhythmic drugs (AAD) and an incomplete pathophysiological
understanding of the disease.
Catheter-based pulmonary vein antrum isolation (PVAI) [2] is most
effective in patients with paroxysmal AF [3,4] and normally sized leftability and freedom from bias of
gy, Academic Medical Center,
nds. Tel.: +31 20 5669111;
.
.atria. In patients withmore advanced diseasemultiple catheter ablation
procedures or extensive ablation within the left atrium and of other
triggers of AF may be needed to achieve an acceptable success rate [5].
Thoracoscopic pulmonary vein isolation (PVI) is an effective treatment
for AF [6–8], but is more invasive than catheter ablation, and has a suc-
cess rate of 69% in an unselected population [7]. Recently, a randomized
multicenter study comparing catheter ablation and thoracoscopic
surgery, showed superiority of the surgical approach (65.6% vs. 36.5%
arrhythmia freedom at one year) in challenging patients with
remodelled atria or prior failed ablation at the cost of an increase in ad-
verse events [9].
Electrophysiological (EP) guided approaches applied during
thoracoscopic PVI use catheter-derived EP endpoints to improve the
outcome of surgery [10,11]. Electrophysiologists with experience in AF
ablation can assess bidirectional conduction block across ablation lines
with EP techniques (epicardially [10] or endocardially [11]). The collab-
oration between surgeon and EP in assessment of acute conduction
block in one session possibly increases the single-procedure success
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events. In this study we investigate the single procedure efﬁcacy and
safety of EP-guidance, using two different groups with either an epicar-
dial or endocardial guidance of thoracoscopic surgery for AF in selected
patients with remodelled atria or prior failed catheter ablation. This
analysis was designed as an exploration of the value of EP-guidance
during two different EP-guided thoracoscopic surgery approaches in
challenging patients. In both approaches, an electrophysiologist con-
tributes actively in the surgical procedure.
2. Methods
2.1. Patient population
Two centres participated in this study, the Academic Medical Center (AMC) in
Amsterdam and the Maastricht University Medical Center (MUMC), Maastricht. Data
were prospectively collected from consecutive patients with one year follow-up who
underwent EP-guided thoracoscopic surgery for AF, all these patients had an indication
for surgical ablation of AF according to the latest guidelines [5,13]. Inclusion of patients
in this analysis was based on pre-procedural predictors of recurrence that identiﬁed pa-
tients that were considered less amenable to PVI and an earlier randomized study towar-
rant a historical comparison [9,14]. Inclusion criteria were; 1) a left atrial diameter of
40–44 mm and hypertension 2) left atrial diameter of ≥45 mm or 3) previous failed
PVI. Patients with incomplete follow-up, deﬁned as absence of 6 or 12 months outpatient
follow-up, or without an adequate pre-procedural echocardiogram to assess left atrial di-
ameter were excluded [9]. Deﬁnitions, clinical follow-up, classiﬁcation of outcome and
reporting of the results are according to the Heart Rhythm Society/European Heart
Rhythm Association/European Cardiac Arrhythmia Society (HRS/EHRA/ECAS) consensus
statement on catheter and surgical ablation [5].
2.2. Thoracoscopic surgery
Thoracoscopic surgery was employed in both centres, the different surgical proce-
dures and mapping protocols have been described earlier in detail [10,11]. Surgery was
performed under general anaesthesia on the beating heart. Ganglionic plexus (GP) were
located anatomically and functional testing was performed with high frequency stimula-
tion. GPs were subsequently ablated in the majority of patients until no vagal response
could be elicited. Bilateral thoracoscopic PVI was performedwith a radiofrequency bipolar
clamp (AtriCure Isolator Transpolar Clamp, AtriCure Inc.). In patients with persistent AF or
with induction of AF after the thoracoscopic PVI, additional left atrial lesions were created
with a radiofrequency pen (AtriCure Isolator Bipolar Linear Pen and AtriCure Coolrail). In
the epicardial EP-guidedprocedures these lines consisted of theDallas lesion set [15], a su-
perior and trigone line and an inferior line in the ﬁrst 24 patients. In the endocardial EP-
guidedprocedures a left box lesion setwas createdusing a stepwise approach as described
in Pison et al. [11], consisting of a superior line and inferior line, additionally right atrial
lines were created (superior cava line, inferior cava line and intercaval lines) in patients
with an enlarged right atrium and a left isthmus line in patients with a perimitral ﬂutter.
The left atrial appendage (LAA)was clipped using an endoscopic stapling device (EndoGia
stapler, Tyco Healthcare Group), according to surgeon preference.
2.3. Electrophysiological study
In the epicardial EP-guided approach PV entry and exit block was tested completely
epicardially with custom-made electrodes and a diagnostic decapolar EP catheter (Radia
XT, Bard) as described in De Groot et al. [16]. If no entry or exit block could be conﬁrmed
additional ablation with the bipolar clamp was applied until isolation was achieved. Ad-
ditional ablation lineswere tested epicardially and additional touch-up ablationswere de-
livered epicardially with radiofrequency ablation pen (AtriCure Isolator Bipolar Linear
Pen) until bidirectional block was achieved. All measurements were performed and
analysed by an electrophysiologist using a dedicated EP-workstation (Bard Labsystem
PRO 2.4A, Bard) [16]. For the endocardially EP-guided approach patients were heparinised
after the thoracoscopic lesion set was applied and a His bundle and a coronary sinus cath-
eter were introduced through a femoral venous approach. After transseptal puncture, PVs
were mapped and isolation was assessed endocardially with a circular mapping catheter
(Lasso, Biosense Webster). If PVs were not isolated, endocardial touch-up ablations were
delivered with a 3.5-mm-tip catheter (ThermoCool, Biosense Webster). The epicardial le-
sionswere subsequently tested endocardially for conduction block,with endocardial com-
pletion of themitral isthmus line and touch-up of the epicardial lesion set in the absence of
bidirectional conduction block. In patients with a history of typical cavotricuspid depen-
dent atrial ﬂutter an additional right atrial isthmus line was created endocardially. No ab-
lation of complex fractionated atrial electrograms was performed.
2.4. Follow-up
After the procedure, patients were reinstated on their pre-procedural medication, in-
cluding AAD. The ﬁrst three months after the procedure were blanked for the determina-
tion of absence of AF. Patients were followed at the outpatient clinic with ECGs and a 24 h
Holter at 3, 6 and 12 months after the procedure according to the HRS/EHRA/ECAS expertconsensus statement [5]. AADs were discontinued starting from the ﬁrst outpatient visit,
3 months after the procedure.
2.5. Efﬁcacy
Theprimary endpointwas freedomof AF, atrialﬂutter or atrial tachycardia lasting lon-
ger than 30 s on any ECG or Holter monitor after the blanking period without the use of
AAD after 12 months [5]. A secondary outcome was deﬁned as freedom from AF, atrial
ﬂutter or atrial tachycardia with/without the use of AAD after 12 months [5].
2.6. Safety
All adverse events during the peri-procedural period (within 30 days after the proce-
dure) were monitored. Major adverse events were adverse events resulting in permanent
injury or death, requiring intervention for treatment or extending hospital admission for
more than 48 h [5]. All non-major adverse events were classiﬁed as other adverse events.
2.7. Statistical analysis
Data are presented asmean± standarddeviation for normally distributed continuous
variables or median and range for non-normal distribution. Categorical variables are pre-
sented in numbers with percentages. Differences were determined with an independent
Student T-test for normally distributed data or a Mann–Whitney U test for not-normally
distributed data. A Chi-square Test or Fisher's Exact Testwas used for categorical variables.
A univariate analysis was performed using binary logistic regression for failure of treat-
ment at one year follow-up. Postoperative AF-free curves were calculated using the
Kaplan–Meier method and compared with the log-rank test. Statistical analyses were car-
ried out using SPSS, version 19.0. A p-value of b0.05 was considered signiﬁcant.
3. Results
3.1. Patient characteristics
Hundred-and-two patients underwent EP-guided surgery for AF
(Amsterdam n = 50, Maastricht n = 52) between 2008 and 2011.
Seventy-sevenmet the inclusion criteria for this analysis and had a pre-
vious failed catheter ablation, an enlarged left atrium of≥45mmor hy-
pertension and an enlarged left atrium 40–44 mm. Five patients were
excluded due to insufﬁcient follow up data (n = 3) or pre-procedural
echocardiogram (n = 2) that precluded quantiﬁcation of the left atrial
diameter. In the remaining72patients, 31 (43%) had a previous catheter
ablation, 48 (67%) had a left atrial diameter of≥45mmand 9 (13%) had
a left atrial size of 40–44 mm with hypertension. Mean age was 59 ±
8.7 years (range 38–78) and 57 patientsweremale (79%). Thirty-six pa-
tients had paroxysmal AF (50%), 32 persistent AF (44%) and 4
longstanding persistent AF (6%). Eighteen patients (25%) had one previ-
ous PVAI, 13 (18%) had two or more previous PVAI. These procedures
consisted either of a PVAI (n = 20) or PVAI with additional left atrial
lesions (n = 11). The results of patients with persistent and
longstanding persistent AF are combined and reported as persistent
AF. Patient characteristics are shown in Table 1.
3.2. Electrophysiological guided procedure
A total of 36 procedures with an epicardial EP-guided approach
(Amsterdam) and 36 with an endocardial EP-guided approach
(Maastricht) were performed. In all but one procedure (with complete
PV isolation after previous catheter ablation) PVI was performed. Of the
22 patients with quantitative information available on the number of
ablation in the epicardial EP-guided approach 11 (50%) patients
achieved PV isolation after 3–14 initial ablations (median 6.5). Addi-
tional epicardial ablation was performed, guided by the epicardial EP
measurements, until bidirectional block was attained. Four patients
(11%) in the endocardial EP-guided approach needed endocardial
touch-up after a total of 6 epicardial ablations. In 48 patients (67%) ad-
ditional atrial lesionswere created; left atrial lesions in all, and addition-
al right atrial lesions in 13 (18%). In the epicardial EP-guided approach
epicardial EP measurements revealed residual conduction across at
least one additional ablation line in all patients, and further epicardial
ablation was performed until bidirectional block was attained. In the
endocardial EP-guided approach the left atrial lines needed additional
Table 1
Patient characteristics.
Patient characteristics All Epicardial Endocardial p-Value
EP-guided EP-guided
Patients, n(%) 72 (100) 36 (50) 36 (50)
Age (years) 59 ± 8.7 (38–78) 59 ± 8.2 (43–77) 60 ± 9.2 (38–78) 0.86
Male, n(%) 57 (79) 30 (83) 27 (75) 0.38
Body mass index (kg/m2) 28 ± 3.7 (21–37) 29 ± 4.3 (22–37) 27 ± 3.0 (21–36) 0.12
CHA2DS2VASc-score, 1 (0–7) 1 (0–6) 1 (0–7) 0.63
Congestive heart failure, n(%) 3 (4) 1 (3) 2 (6) 1.00
Hypertension, n(%) 30 (42) 14 (39) 16 (44) 0.63
Age ≥ 75, n(%) 3(4) 2 (6) 1 (3) 1.00
Diabetes, n(%) 1 (1) 1 (3) 0 (0) 1.00
Stroke/TIA/embolus, n(%) 6 (8) 5 (14) 1 (3) 0.20
Vascular disease, n(%) 7 (9) 2 (6) 5 (14) 0.43
Age ≥ 65, n(%) 15 (21) 10 (28) 12 (33) 0.61
History of atrial ﬂutter, n(%) 13 (18) 1 (3) 12 (33) 0.01
Previous atrial ﬂutter ablation, n(%) 8 (11) 1 (3) 7 (19) 0.55
Type AF
Paroxysmal, n(%) 36 (50) 17 (47) 19 (53) 0.64
Persistent, n(%) 36 (50) 19 (53) 17 (47) 0.64
Total duration of AF, median, range (years) 5.5 (1–22) 6 (2–22) 4.5 (1–13) 0.09
Previous catheter PVI
1 18 (25) 9 (25) 9 (25) 1.00
2≥ 13 (18) 7 (19) 6 (17) 1.00
Echocardiography
Left atrial sizea, (mm) 47 ± 6.2 (32–61) 50 ± 6.4 (40–61) 44 ± 4.8 (32–53) b0.01
AF: atrial ﬁbrillation, EP; electrophysiological, PVI: pulmonary vein isolation, TIA: transient ischemic attack.
a Left atrial diameter measured on the parasternal long axis.
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the majority of patients (n = 44, 61%). LAA removal was performed in
45 patients (63%).Mean procedure timewas 218±79min and average
admission duration was 6.5 ± 3 days. Procedure characteristics are
shown in Table 2.
3.3. Efﬁcacy
After one year and after discontinuation of AAD 57 patients (79%)
had sinus rhythm and no recurrences of AF, atrial ﬂutter or atrial
tachycardia, of whom 30 patients with paroxysmal AF (83%) and 27
with persistent AF (75%). Of note, most patients with recurrences,
(AF n = 6, AF and AT n = 3, AT n = 2, AFT n = 1) presented them-
selves with complaints of palpitations at a physician (10/12). The
majority were managed with anti-arrhythmic drugs as these
patients had far less symptoms than before the procedure. A redoTable 2
Procedure characteristics.
Procedure characteristics All
Procedures, n (%) 72 (100)
PVI Isolation, n (%) 71 (99)
GP ablation, n(%) 44 (61)
Additional left atrial ablation lines, n(%) 48 (67)
Rooﬂine, n(%) 48 (67)
Floor line, n(%) 38 (53)
Trigone line, n(%) 11 (15)
LAA line, n(%) 6 (8)
Mitral isthmus line, n(%) 3 (4)
Intercaval line, n(%) 11 (15)
Superior vena cava line, n(%) 11 (15)
Inferior vena cava line, n(%) 3 (4)
Right isthmus line, n(%) 6 (8)
LAA removed, n(%) 45 (63)
Procedure duration, (min) 219 ± 79 (75–540)
Duration of hospital stay, (days) 6 (3–13)
GP: ganglionic plexus, EP; electrophysiological, LAA: left atrial appendage, PVI: pulmonary veincatheter ablation was performed in 3 patients. Two patients showed
intact ablation lines endocardially and only an additional mitral isth-
mus line was created. One of these patients achieved no sinus
rhythm after the ablation and has subsequently been treated with
rate control. The third patient had a redo-isolation of a common os-
tium and additional touch-up of the roof line, this patient has had
no recurrences after this redo-procedure. Three patients still used
AAD due to patient preference. Absence of AF at one year including
these three patients was present in 60 patients (83%) in the entire
cohort; in 32 (89%) and 28 (78%) patients with paroxysmal and per-
sistent AF respectively. An overview of the outcome endpoints is
shown in Table 3.
Three factors were associated with failure in univariate analysis.
Thesewere female sex (odds ratio 3.6, CI 1.014–12.467, p= 0.048), pres-
ence of vascular disease (odds ratio 6.5, CI 1.281–33.451, p= 0.024) and
duration of AF (odds ratios 1.168, CI 1.018–1.339, p = 0.022).Epicardial Endocardial p-Value
EP-guided EP-guided
36 (50) 36 (50)
36 (100) 35 (97) 1.00
35 (97) 9 (25) b0.01
18 (50) 30 (83) 0.03
18 (50) 30 (83) 0.03
10 (28) 28 (78) b0.01
11 (31) 0 (0) b0.01
6 (17) 0 (0) 0.25
0 (0) 3 (8) 0.24
0 (0) 11 (31) b0.01
0 (0) 11 (31) b0.01
0 (0) 3 (8) 0.24
0 (0) 6 (17) 0.25
34 (94) 11 (31) b0.01
219 ± 82 (120–540) 218 ± 76 (75–505) 0.98
5 (3–12) 6 (5–13) 0.07
isolation.
Table 3
Outcome.
Efﬁcacy All Epicardial Endocardial
EP-guided EP-guided
HRS/ESC/EHRA success, n(%) 57 (79) 27 (75) 30 (83)
Paroxysmal AF, n(%) 30 (83) 15 (88) 15 (79)
Persistent AF, n(%) 27 (75) 12 (63) 15 (88)
HRS/ESC/EHRA with AAD success, n(%) 60 (83) 28 (78) 32 (89)
Paroxysmal AF, n (%) 32 (89) 16 (94) 16 (84)
Persistent AF, n(%) 28 (78) 12 (63) 16 (94)
AAD; anti-arrhythmic drugs, EP; electrophysiological, AF; atrial ﬁbrillation.
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No patient died during the procedure or during follow-up. There
were 6 major adverse events. Two patients received a sternotomy to
control bleeding, which could not be managed thoracoscopically. The
hematothorax that occurred in two other patients, resulted from an in-
tercostal artery bleeding. Careful retraction of theworkingport andﬁnal
inspection before closure has prevented this event from occurring in all
subsequent patients. One patient received a pacemaker due to a brady-
cardia induced torsade de pointes. One patient developed a pericardial
effusion three weeks after the procedure, after drainage the patient re-
stored without any further complications. No phrenic nerve palsies de-
veloped as the thoracoscopic approach allows very clear visualisation of
the phrenic nerve and the pericardium was opened N1 cm away from
the nerve. Therewere no irreversible injuries and all bleeding complica-
tions that occurredwere surgical related anddid not occur during the EP
measurements. An overview of the adverse events is listed in Table 4.
3.5. Patient population of epicardial and endocardial electrophysiological
guided procedure
The patient population in both centres is similar, due to the inclu-
sion criteria for this analysis (Table 1). Signiﬁcant differences be-
tween the centres were a higher number of patients with a history
of ﬂutter in the endocardial EP-guided group (p = 0.01) and larger
atrial dimensions in the epicardial EP-guided group (p b 0.001).
Not signiﬁcant, but noticeable differences include more patients
with a history of stroke, TIA and/or a systemic embolus (p = 0.20),
a higher BMI (p = 0.12), and longer duration of AF (p = 0.09) in
the epicardial EP-guided group. Procedure characteristics were signiﬁ-
cantly different due to the differences in the approach of the EP mea-
surements and additional ablations (GP ablation, type of additional
ablation lines, LAA removal), but did not correlate with success. Nota-
bly, procedure duration and admission duration were similar (p =
0.98 and p = 0.07 respectively). Between the different procedures,
there were no signiﬁcant differences in outcome, neither overall norTable 4
Peri-procedural complications.
Mortality and mortality All
Mortality, n(%) 0 (0)
All adverse events, n(%) 13 (18
Major adverse events, n(%) 6 (8.3
Conversion of surgery, n(%) 2 (2.8
Pacemaker implantation, n(%) 1 (1.4
Hematothorax requiring surgical intervention, n(%) 2 (2.8
Pericardial effusion, n(%) 1 (1.4
Other adverse events, n(%) 7 (9.7
Pneumonia, n(%) 3 (4.2
Pneumothorax, n(%) 2 (2.8
Wound problems, n(%) 1 (1.4
Heart failure, n(%) 1 (1.4
EP; electrophysiological.for subgroups (Fig. 1). Finally, no signiﬁcant differences were found in
adverse events.4. Discussion
The management of AF in patients with enlarged atria or previous
failed catheter ablation presents a challenge. In this study two different
EP-guided surgical approaches were performed in a group consisting of
challenging patients with AF. A total of 79% of patients undergoing one
single EP-guided thoracoscopic procedure for AF remained free of AF
during one year without the use of AAD.4.1. Electrophysiological guidance during thoracoscopic surgery
Recently, a randomized multicenter study comparing catheter abla-
tionwith non-EP guided thoracoscopic surgery in a group of challenging
patients reported a success rate of 36.5% versus 65.6% respectively after
one year follow-up without AAD, but at the cost of more procedural ad-
verse events: 23.0% vs. 3.2% [9]. The patients described in our study, se-
lected on similar inclusion criteria, are therefore not ideal candidates for
catheter ablation.Half of thepatients (43%) had anearlier failed ablation
and 67% of the patients had a severely enlarged LA with or without
hypertension, pre-procedural predictors of recurrence [14]. In these se-
lected patients EP-guided thoracoscopic surgery results in an increased
efﬁcacy of 79%, when compared to the published results of standalone
thoracoscopic surgery in similar patient cohorts [6,7,9]. There appears
to be an addition of EP-guidance in the two different procedures, irre-
spective of the differences in the two approaches. These similar out-
comes might be the result of the underlying philosophy of EP
guidance; the enhanced resolution and ability to conﬁrm conduction
block and to detect gaps in ablation lines during thoracoscopic surgery.
Our data show that in 11–50% of the procedures the PVs were not fully
isolated after the initial surgical ablation attempt and that depending on
the additional atrial lesion set used, all ablation lines required additional
epicardial or endocardial touch-up. The difference in the integrity of PV
isolation between the approaches could be partially attributed to differ-
ences in the number of applications at the initial attempt. In the epicar-
dial EP-guided approach the duration of clamping was based on an
impedance measurement during ablation, reﬂecting “transmurality” of
the lesion. The duration of applicationswas about 15 s in the endocardi-
al EP-guided approach. The technical complexity in creating the trigone
line could explain the frequency of incomplete block found after theﬁrst
ablation attempt. Further study of these procedures is required in differ-
ent populations and in prospective randomised trails against stand-
alone surgery and catheter ablation to clarify the role and additive effect
of EP-guidance in the (surgical) treatment of AF.Epicardial Endocardial
EP-guided EP-guided
0 (0) 0 (0)
.1) 8 (22.2) 5 (13.9)
) 5 (13.9) 1 (2.8)
) 1 (2.8) 1 (2.8)
) 1 (2.8) 0 (0)
) 2 (5.6) 0 (0)
) 1 (2.8) 0 (0)
) 3 (8.3) 4 (11.1)
) 2 (5.6) 1 (2.8)
) 1 (2.8) 1 (2.8)
) 0 (0) 1 (2.8)
) 0 (0) 1 (2.8)
Fig. 1. FreedomofAF in subgroups. Kaplan–Meier curve representing thepercentage estimates of patientswith freedomof AFup to one year after surgery. PanelA: freedomof AF curves for
two participating centres (log-rank test p = 0.45). Panel B: freedom of AF curves according to different types of AF (log-rank test p = 0.70). Panel C: freedom of AF curves in left atrial
diametermore or less than 45mm (log-rank test p= 0.79). Panel D: freedomof AF curves stratiﬁed according to a history of previous catheter ablation (log-rank test p= 0.69). AF; atrial
ﬁbrillation, EP; electrophysiological, LA; left atrium, PVI; pulmonary vein isolation.
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Both procedures had similar cornerstones with a patient tailored
approach [5]; PVI and left atrial lesions which were extensively
tested with epicardial or endocardial mapping, however there were
other procedural differences. The patients with an endocardial EP-
guided approach received a more extensive lesion set, using a step-
wise approach, with the inclusion of right atrial lesions. Potentially,
right atrial lesions are necessary in patients with persistent AF or en-
larged right atria to achieve a better result [17]. On the other hand,
patients with paroxysmal AF might beneﬁt more from PVI alone
[18]. In a majority of the patients the GPs were ablated or the LAA
was removed, however the success rate in these two groups was
not different. This may be due to the patient selection of this analysis.
In these patients the substrate of AF may be less dependent of GP
function and extrapulmonary triggers may play a smaller role. It is
still not univocally clear whether GP ablation during minimal inva-
sive surgery for AF has additional beneﬁt [6,7]. Catheter ablation
studies have shown, that functional localization and ablation of
GP's, with a vagal response on high frequency stimulation, are less
effective than anatomical ablation [19]. In this study a primarily
anatomical approach was used, with functional conﬁrmation. It may
well be that epicardial ablation of the PVI with the use of a RF clamp
interrupts the innervation of the PV's.The success rates after one year are the same as the included groups
in this study (Fig. 1). Interestingly, patients with an atrium b45mm ap-
pear to have mostly late recurrences (after 276 days), possibly indicat-
ing a subgroup of patient with progression of underlying atrial
remodelling, but the number of recurrences is low. Female sex, vascular
disease and longer duration of AF were associated with recurrences in
this population. While these factors could not be validated in multivar-
iate analysis, they have been reported earlier [20,21]. Patients who
underwent an epicardial EP-guided procedure were heavier, had larger
atria and a non-signiﬁcant longer duration of AF, possibly associated
with an increased recurrence risk [5,20,22,23].
4.3. Left atrial appendage exclusion
In the majority of our patients the LAAwas excluded. In the remain-
ing patients the LAA was not excluded due to anatomical restrictions or
surgeon preference. LAA removal can cause bleeding, which might re-
quire conversion to sternotomy [6,24]. Its effect on left atrial function
and remaining thromboembolic risk is incompletely understood [25],
and further study would be needed to clearly deﬁne the risks and ben-
eﬁt of surgical LAA occlusion. Moreover, removal of the LAA may con-
tribute to the elimination of extra-pulmonary vein triggers of AF [26],
however LAA removal was not associated with an increased success
rate in our small population. This issue becomes more relevant as the
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growing patient population receives invasive treatment for AF with
exclusion of the LAA. After catheter ablation stroke risk is reduced
[23], but LAA exclusion might even further decrease stroke risk in
patients with a high CHA2DS2-VASc score [27,28].
4.4. Safety of electrophysiology guided thoracoscopic surgery
In 18% of the patients reversible adverse events occurred. These
ranged from major events, requiring additional interventions and
prolonging hospital stay, to minor events, that required no intervention.
The rate of adverse events is similar as reported in literature [6,7,9], but
remains signiﬁcant when compared to catheter ablation [4]. It is impor-
tant to note that these results are obtained in the ﬁrst series of patients
treated with EP-guided surgery for AF. The hematothorax that occurred
in two consecutive patients, for instance, resulted from an intercostal ar-
tery bleeding. Careful retraction of the working port and ﬁnal inspection
before closure has prevented this event from occurring in all subsequent
patients. Also, the rate of adverse events is expected to lie between that
in catheter ablation and the Cox-Maze IV procedure [29]. Some of these
patients would be considered eligible for Cox-Maze IV surgery, however
thoracoscopic surgery is less invasive than a Cox-Maze IV procedure.
Most minor events are a direct mechanical consequence of the
thoracoscopic approach. The risk of stroke is relatively low in
thoracoscopic surgery and no strokes have occurred in this cohort [30].
Whilst a combination of catheterization in addition to surgery has the
risk of both procedures, absolute risk is not cumulative as shown in our
data which showmainly surgical complications. Themajority of ablation
is performed epicardially. Subsequently, endocardial ablation times are
severely reduced in the endocardial EP-approach reducing the likelihood
of PV stenosis and atrio-oesophageal ﬁstula. Finally, these patients repre-
sent a groupwith advanceddiseasewhich is often a representation of the
general health and might therefore be more prone to adverse events.
However, no patient characteristics correlatedwith the occurrenceof ad-
verse events. None of the adverse events occurred during the EP mea-
surements, epicardial or endocardial, either of which appears a safe
addition to thoracoscopic surgery for AF.
4.5. Limitations
This is a retrospective study, of prospectively collected data, investi-
gating two different approaches of EP-guided surgery for AF in selected
challenging patients. Of all included patients, 16 patients from the AMC
and 22 from theMUMC have been previously reported in two unselect-
ed observational analyses [10,11]. The 5 patients with inadequate pre-
procedural data or incomplete follow-up were excluded to prevent
overestimation of successful cases. The excluded patients all demon-
strated sinus rhythm at one year follow-up according to the available
data. No implantable loop recording was used to detect recurrences,
and therefore the success rate might be an overestimation of true suc-
cess [31]. However, follow-up was organized to comply with the HRS/
EHRA/ECAS consensus statement and reﬂects clinical practice in most
centres. This study is a result of pooled data of two centreswith a differ-
ent thoracoscopic procedure and EP approach, butwith a similar philos-
ophy in the implementation of EP measurements during surgery. These
different approaches illustrate that EP measurements per se can
complement stand-alone surgery for AF in this selected group of
difﬁcult patients. However, this is not a randomized study and the aim
was not to compare the two approaches, or to compare EP-guided
surgery with stand alone surgery or catheter ablation.
5. Conclusion
EP-guided surgical ablation for AF is effective in patients with en-
larged left atria or a previously failed ablation with a success rate of
79% at one year without AAD. EP guidance of the procedure can beperformed safely, either using an epicardial or using an endocardial ap-
proach, and may contribute to the success rate. A heart-team approach
with close cooperation between surgeons and cardiologist resulting in
an EP-guided surgical ablation provides a new and promising treatment
modality for these, often difﬁcult to treat, patients. Further randomized
studies are recommended to compare the added value of EP-guided
surgery in the current era of invasive treatment of AF.
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